Envudeucitinib achieves 54% PASI 100 at 48 weeks; NDA on track for 4Q 2026

ALUMIS INC.

54% of patients achieved PASI 100 (complete skin clearance) at 48 weeks; 75% achieved PASI 90.
Integrated analysis (890 pts) showed 66% PASI 90 and 47% PASI 100 at 48 weeks.
1,509 patients rolled into ONWARD3 from ONWARD1/2 (>85% rollover); safety consistent, no new signals.
NDA submission to FDA planned for 4Q 2026; LUMUS Phase 2b SLE topline expected 3Q 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.